The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2017 | Necitumumab plus pembrolizumab: a viable alternative for NSCLC
Benjamin Besse, MD, PhD, from the Gustave Roussy Cancer Institute, Paris, France, discusses a recent study he authored at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. This study (NCT02451930) investigated the efficacy of pembrolizumab plus necitumumab in a cohort of approximately 64 patients, half with squamous histology, half with non-squamous. The toxicity of the combination is more severe than the individual agents, however, the combination appeared to be well tolerated. Despite this, the response rate wasn’t high enough to proceed investigations with this combination.
